Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Breast Cancer Research and Treatment • 2004 | View Paper
“On days 2 and 29, liarozole was given 1 h prior to ingestion of all-trans RA at single doses ranging from 75 to 300 mg.”
“We conclude that liarozole at a dose of 300 mg effectively attenuates the induced decline in all-trans RA plasma concentrations that occurs with continuous treatment.”
Cancer Chemotherapy and Pharmacology • 2004 | View Paper
“ Liarozole is an imidazole‐like compound that inhibits the retinoic acid (RA) 4‐hydroxylase‐mediated breakdown of all‐trans RA, causing elevation of plasma and cutaneous levels of RA.”
The British journal of dermatology • 2001 | View Paper
“ Liarozole is a 1-substituted imidazole derivative that inhibits cytochrome P450 activity and increases endogenous plasma concentrations of retinoid acid (RA).”
“The imidazole derivative liarozole is a potent inhibitor of cytochrome P450‐dependent 4‐hydroxyla‐tion of endogenous all‐trans retinoic acid , thereby increasing the levels of all‐trans retinoic acid in both plasma and skin.”
The British journal of dermatology • 1998 | View Paper
“ Liarozole is an imidazole derivative that has been identified as an inhibitor of the cytochrome P450‐dependent all‐trans retinoid acid (RA) breakdown.”